Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
Launched by AKORN, INC. · May 10, 2018
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- IInclusion Criteria:
- • Male or non-pregnant, non-lactating female, ≥12 and ≤40 years of age with a clinical diagnosis of acne vulgaris.
- • Have facial acne with: ≥20 facial inflammatory lesions (papules and pustules) and ≥25 non-inflammatory lesions (open and closed comedones), and ≤2 nodulocystic lesions (nodules and cysts) and have an IGA score of 2, 3 or 4.
- Exclusion Criteria:
- • Subject has more than 2 facial nodular lesions; any nodules present will be documented but not included in the inflammatory lesion count for analysis.
- • Subject has active cystic acne.
- • Subject has acne conglobata.
- • Subjects with excessive facial hair such as beards, sideburns, moustaches, etc. that would interfere with the diagnosis or assessment of acne.
About Akorn, Inc.
Akorn, Inc. is a specialty pharmaceutical company focused on the development, manufacturing, and marketing of prescription and over-the-counter pharmaceuticals. With a strong emphasis on high-quality products, Akorn leverages advanced technologies and a robust pipeline to deliver innovative solutions across various therapeutic areas, including ophthalmology, anesthesiology, and dermatology. Committed to improving patient outcomes, the company prioritizes rigorous clinical trials and regulatory compliance, ensuring that its offerings meet the highest standards of safety and efficacy. Akorn's dedication to excellence and patient-centric approach positions it as a key player in the pharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Encino, California, United States
Sherman Oaks, California, United States
Brandon, Florida, United States
Miramar, Florida, United States
Miramar, Florida, United States
Tampa, Florida, United States
Tampa, Florida, United States
High Point, North Carolina, United States
El Paso, Texas, United States
El Paso, Texas, United States
Belize City, , Belize
Belize City, , Belize
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials